Skip to main content
Menu
About Us
Overview
Mission
Our Story
Our Team
Technology
RNAa
Delivery Platforms
Additional Technology
Intellectual Property
Publications & Presentations
Pipeline
Overview
Clinical Programs
Expanded Access
Partnerships
Academic Collaborations
Industrial Partnerships
News & Events
Join Us
Life at Ractigen
Current Job Openings
Contact
中文
Press enter to begin your search
Close Search
News
July 25, 2024
in
Homepage News
,
News Highlight
Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy
JIANGSU, China, July 25, 2024 -- Ractigen Therapeutics, a pioneering developer of small activating RNA…
Read More
January 27, 2022
in
Company News
,
Homepage News
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…
Read More
February 10, 2021
in
Company News
,
Homepage News
Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
Read More
May 19, 2020
in
Company News
,
Homepage News
CB Insights lists Ractigen as one of the Top RNA biotech companies in China
Today, CB Insights China published, for the first time, a top list of RNA biotech…
Read More
Close Menu
About Us
Overview
Mission
Our Story
Our Team
Technology
RNAa
Delivery Platforms
Additional Technology
Intellectual Property
Publications & Presentations
Pipeline
Overview
Clinical Programs
Expanded Access
Partnerships
Academic Collaborations
Industrial Partnerships
News & Events
Join Us
Life at Ractigen
Current Job Openings
Contact
中文
